Login to Your Account



Clinic Roundup


Thursday, December 30, 2010
• Ziopharm Oncology Inc., of New York, dosed its first patient in a Phase I trial of ZIO-201 (palifosfamide) with etoposide and cisplatin/carboplatin for small cell lung cancer. Palifosfamide is currently in Phase III for soft tissue sarcoma. The trial is being carried out at the Indiana University Cancer Center and will enroll 12 to 15 patients. It will evaluate safety of the combination drug regimen for a planned randomized Phase II trial.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription